Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

The Lancet. Respiratory Medicine
Luana CalabròMichele Maio

Abstract

Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first-line or second-line chemotherapy compared with placebo in the DETERMINE study. We aimed to investigate the efficacy and safety of first-line or second-line tremelimumab combined with durvalumab, an anti-PD-L1 monoclonal antibody, in patients with malignant mesothelioma. In this open-label, non-randomised, phase 2 trial, patients with unresectable pleural or peritoneal mesothelioma received intravenous tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses. The primary endpoint was the proportion of patients with an immune-related objective response according to the immune-related modified Response Evaluation Criteria in Solid Tumors (RECIST; for pleural mesothelioma) or immune-related RECIST version 1.1 (for peritoneal mesothelioma). The primary analysis was done by intention to treat, whereas the safety analysis included patients who received at least one dose of study drug. This trial is regist...Continue Reading

Citations

Jun 27, 2018·Cancer Immunology, Immunotherapy : CII·Luana CalabròMichele Maio
Jul 27, 2018·Journal of Clinical Pharmacy and Therapeutics·Gregory M PetersonInger H Olesen
Feb 15, 2019·Current Treatment Options in Oncology·Patrick M FordeAnne S Tsao
Jul 6, 2019·Expert Opinion on Biological Therapy·Juliana Alvarez-Argote, Constantin A Dasanu
Apr 12, 2020·Cancers·Fabio NicoliniMassimiliano Mazza
Feb 27, 2020·Journal for Immunotherapy of Cancer·Katsuyuki Hotta, Nobukazu Fujimoto
May 26, 2020·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Isabelle OpitzGiuseppe Cardillo
May 3, 2019·Expert Opinion on Biological Therapy·Anna K NowakAlistair Cook
May 18, 2019·American Society of Clinical Oncology Educational Book·Christine L HannHeather A Wakelee
Mar 11, 2020·Frontiers in Oncology·Cornedine J de GooijerPaul Baas
May 20, 2020·Frontiers in Immunology·Mengxiao XieJian Xu
Jun 26, 2020·Frontiers in Oncology·Robert A BelderbosJoachim G J V Aerts
May 27, 2020·The European Respiratory Journal·Arnaud ScherpereelPaul Martin Putora
Oct 19, 2019·Nature Reviews. Clinical Oncology·Anna K Nowak, Patrick M Forde
May 7, 2020·Journal of Hematology & Oncology·Jifeng YuWenzhi Tian
Nov 10, 2018·F1000Research·Lawek Berzenji, Paul Van Schil
Aug 1, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Yeon Seung ChungHyo Sup Shim
Jun 26, 2020·International Journal of Molecular Sciences·Omid KooshkakiBehzad Baradaran
Dec 20, 2018·Cancer Immunology, Immunotherapy : CII·Anna Maria Di GiacomoMichele Maio
Feb 11, 2020·Frontiers in Oncology·Fabio NicoliniMassimiliano Mazza
Jul 19, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aaron S Mansfield, Marjorie G Zauderer
Jun 27, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dmitriy ZamarinDavid S Hong
Dec 29, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ondine BeckerSarah Watson
Oct 17, 2020·Therapeutic Advances in Medical Oncology·Liu JinZhongwen Chen
Nov 27, 2020·Therapeutic Advances in Medical Oncology·Haitang YangRen-Wang Peng
Mar 18, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jordi RemonGiorgio V Scagliotti
Dec 29, 2020·Clinical Lung Cancer·Dipesh Uprety

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.